📰 Full Story
On April 18, 2026 President Donald Trump signed an executive order directing federal agencies to fast-track research, review and potential access to certain psychedelic drugs, spotlighting ibogaine as a priority.
The order instructs the Food and Drug Administration to expedite reviews and issue national priority review vouchers for three psychedelics, opens a pathway under the Right to Try law for desperate patients, and directs coordination among HHS, the FDA and the Department of Veterans Affairs to boost clinical trials and data sharing.
The administration said it will allocate $50 million for federal support of ibogaine research, matching prior state-level commitments such as Texas’s $50 million.
Trump signed the order in the Oval Office flanked by veterans, HHS Secretary Robert F. Kennedy Jr., FDA Commissioner Marty Makary and podcaster Joe Rogan.
Advocates hailed the move as a breakthrough for treating PTSD, traumatic brain injury and addiction, while scientists and public-health officials warned that most psychedelics remain Schedule I substances and that ibogaine carries documented cardiac risks and limited large-scale trial evidence.
Officials said regulatory decisions could come rapidly, potentially as soon as this summer.







💬 Commentary